BeStock  
Stocks › Biotechnology › ELVN

Enliven Therapeutics ELVN

US equityMarket cap rank #2338Biotechnology
$46.53 +$0.12 (+0.26%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $46.53 0.00%
Open$46.05
Prev close$46.41
Day range$45.64 – $47.83
Volume933.6K
Market cap$3.42B
P/E (TTM)–
Dividend yield–

Price chart

Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.

ELVN at a glance

Enliven Therapeutics (ELVN) is trading at $46.53, up 0.26% on the day. Its market value of $3.42B makes it the 2338th largest of the 3753 companies we follow.

The stock's 52-week band runs $14.79 to $62.32, and the latest print sits 25.3% under the top end of it. Holders are ahead 113.9% over twelve months, but down 23.9% across the last three months.

On the chart it holds above both the 50-day ($45.34) and 200-day ($44.31) moving averages; RSI is 50, and the last 30 sessions moved at roughly 57% annualized volatility.

For the quarter ended Sep 2026 it reported $0.00 in revenue, and a net loss of $27.70M.

10 analysts follow the stock and the average call is "buy". The mean target, $74.88, sits 60.9% over where the stock trades.

This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.

Key statistics

Bid / Ask$38.00 / $48.00
Average price today$46.59
Volume933.6KAvg (90d) 1.24M
Turnover$43.50M
Turnover rate1.44%of shares outstanding
Volume ratio1.15vs. recent average pace
Day amplitude4.72%
Market cap$3.42B
Float market cap$3.02B
Shares outstanding64.84M
EPS (TTM)-$1.83
P/B3.90
Book value / share$11.92
Net profit (TTM)-$134.68M
Net assets$876.96M
30-day volatility56.9%annualized
Avg daily range (ATR)5.39%of price, 14 days
Max drawdown (1y)-39.0%-23.9% from 1y peak

Quote as of Nov 20, 2026 8:20 pm ET. Prices can lag the live tape. This is background information, not a recommendation.

BeStock Grade

C
BeStock Grade

Composite of 3 factors below, ranked against the 3734 U.S. stocks BeStock covers.

B
Valuation

Cheaper than usual on its own 5-year P/E history scores higher.

C
Momentum

Trading closer to its 52-week high than most peers scores higher.

B
Wall Street

10 analysts, consensus Buy.

How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.

Six-factor research snapshot

Overall percentile: 67.3 · 2026-11-22 14:27 UTC. Higher values indicate a stronger relative ranking.

FactorPercentile
Valuation—
Growth—
Profitability6.8
Momentum64.2
Financial health99.9
Analyst view83.4

Price forecast

What Wall Street analysts and Morningstar's fair-value model expect for the stock

Analyst price target (avg)$74.88+60.9% vs. current price
Consensus ratingBuy10 analysts covering
Morningstar fair value$58.64Price is below fair value

Wall Street’s average 12-month target is $74.88, 60.9% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $58.64, so shares trade 20.7% below that estimate. On earnings multiple, it sits in the 19th percentile of its own five-year valuation range (cheaper than usual).

Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.

Performance

Price return over each window, from adjusted daily and weekly closes

1 day
+0.3%
1 week
-4.7%
1 month
+11.0%
3 months
-23.9%
6 months
+12.0%
Year to date
+202.1%
1 year
+113.9%
Day range
$45.64$47.83
52-week range
$14.79$62.32

Technical signals

Full technicals →
Trend readLeaning bullish

4 bullish · 3 bearish of 7 signals

IndicatorValueSignal
Price vs 20-day average-0.3%Bearish
Price vs 50-day average+2.6%Bullish
Price vs 200-day average+5.0%Bullish
50-day vs 200-day50d above 200dBullish
RSI (14)50.4Bullish
MACD (12,26,9)0.58Bearish
Bollinger band position49%Bearish

Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.

How ELVN ranks on BeStock

Market value#2329 of 3734
Closeness to 52-week high#1853 of 3724
Dollar volume today#1525 of 3734

Ranks are among the 3,734 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.

ELVN is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.

Since 2020-12-28, the strategy has returned 401.7% (183.6% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated daily — not a guarantee of future results, and not a BeStock recommendation.

Strategy Backtest

Pick a strategy above and run the backtest to see its simulated performance on ELVN.

Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.

Community Sentiment on ELVN

No votes yet — be the first to weigh in.

Reader sentiment, not investment advice. One vote per visitor; click again to change it.

ELVN stock: common questions

What is ELVN's latest share price?

$46.53 is the latest print for ELVN, a move of +0.26% against yesterday's close of $46.41. Today's low and high so far: $45.64 and $47.83.

How big is Enliven Therapeutics?

Equity value comes to $3.42B at the current price. By that measure it is number 2338 of the 3753 names in our coverage.

Is ELVN near its 52-week high or low?

The year's floor is $14.79 and the ceiling $62.32. Shares are 25.3% away from that ceiling.

Does Enliven Therapeutics pay a dividend?

Our data shows no dividend paid by Enliven Therapeutics over the trailing twelve months.

Is ELVN rated a buy by Wall Street?

Of 10 analysts, 100% say buy, 0% hold and 0% sell. Price targets average $74.88, with the most cautious at $70.00 and the most optimistic at $82.00.

BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.

Discussion

No comments yet — be the first to weigh in on ELVN.

Sign in to join the discussion.

Scroll to Top